{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T00:06:32Z","timestamp":1788912392337,"version":"build-2803163510"},"reference-count":42,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,6,25]],"date-time":"2026-06-25T00:00:00Z","timestamp":1782345600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T00:00:00Z","timestamp":1788912000000},"content-version":"vor","delay-in-days":76,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"the Jiangsu Provincial Elderly Health Research Project","award":["No. LKM2024043"],"award-info":[{"award-number":["No. LKM2024043"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"DOI":"10.1186\/s12885-026-16412-5","type":"journal-article","created":{"date-parts":[[2026,6,25]],"date-time":"2026-06-25T01:45:53Z","timestamp":1782351953000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Therapeutic outcomes of PD-1 blockade-related regimens versus docetaxel in previously immunotherapy-treated advanced non-small cell lung cancer: a retrospective, exploratory study"],"prefix":"10.1186","volume":"26","author":[{"given":"Ting-Ting","family":"Huang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin-Ying","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qin","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peng-Fei","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,25]]},"reference":[{"issue":"3","key":"16412_CR1","doi-asserted-by":"publisher","first-page":"229","DOI":"10.3322\/caac.21834","volume":"74","author":"F Bray","year":"2024","unstructured":"Bray F, Laversanne M, Sung H, et al. Global cancer statistics 2022: Globocan estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024;74(3):229\u201363. https:\/\/doi.org\/10.3322\/caac.21834.","journal-title":"CA Cancer J Clin"},{"issue":"1","key":"16412_CR2","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1016\/j.jncc.2024.01.006","volume":"4","author":"B Han","year":"2024","unstructured":"Han B, Zheng R, Zeng H, et al. Cancer incidence and mortality in China, 2022. J Natl Cancer Cent. 2024;4(1):47\u201353. https:\/\/doi.org\/10.1016\/j.jncc.2024.01.006.","journal-title":"J Natl Cancer Cent"},{"issue":"1","key":"16412_CR3","doi-asserted-by":"publisher","first-page":"1408","DOI":"10.1186\/s12885-025-14779-5","volume":"25","author":"MT McMillan","year":"2025","unstructured":"McMillan MT, Reyngold M, Crane CH, et al. A phase II trial of hepatic ablation of metastases to modulate and enhance immunotherapy response in non-small cell lung cancer (Hammer-NSCLC). BMC Cancer. 2025;25(1):1408. https:\/\/doi.org\/10.1186\/s12885-025-14779-5.","journal-title":"BMC Cancer"},{"key":"16412_CR4","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-025-04181-w","author":"Z Huang","year":"2026","unstructured":"Huang Z, Zeng L, Ruan Z, et al. Time-of-day immunochemotherapy in non-small cell lung cancer: a randomized phase 3 trial. Nat Med. 2026. https:\/\/doi.org\/10.1038\/s41591-025-04181-w.","journal-title":"Nat Med"},{"key":"16412_CR5","doi-asserted-by":"publisher","unstructured":"Li X, Wang Z, Mao S, iScience et al. 2026, 29(2):114607. https:\/\/doi.org\/10.1016\/j.isci.2025.114607.","DOI":"10.1016\/j.isci.2025.114607"},{"key":"16412_CR6","doi-asserted-by":"publisher","first-page":"116579","DOI":"10.1016\/j.ejca.2026.116579","volume":"237","author":"M Gemelli","year":"2026","unstructured":"Gemelli M, Sala L, Morabito A, et al. Real-world outcomes of immunotherapy discontinuation at two years in advanced non-small cell lung cancer: Final results of the I-Stop study. Eur J Cancer. 2026;237:116579. https:\/\/doi.org\/10.1016\/j.ejca.2026.116579.","journal-title":"Eur J Cancer"},{"key":"16412_CR7","doi-asserted-by":"publisher","first-page":"572625","DOI":"10.2147\/dddt.s572625","volume":"20","author":"LJ Zheng","year":"2026","unstructured":"Zheng LJ, Shen YL, Zhao HW, et al. Real-World Outcomes and Safety of PD-1 Blockade Rechallenge Strategies After Prior Immunotherapy in Advanced NSCLC: A Retrospective Cohort Study. Drug Des Devel Ther. 2026;20:572625. https:\/\/doi.org\/10.2147\/dddt.s572625.","journal-title":"Drug Des Devel Ther"},{"key":"16412_CR8","doi-asserted-by":"publisher","first-page":"175883592513873","DOI":"10.1177\/17588359251387393","volume":"17","author":"SR Khan","year":"2025","unstructured":"Khan SR, Eiras LM, Boldt G, et al. Antibody-drug conjugates versus docetaxel for previously treated advanced non-small-cell lung cancer: a systematic review and meta-analysis of randomized controlled trials. Ther Adv Med Oncol. 2025;17:17588359251387393. https:\/\/doi.org\/10.1177\/17588359251387393.","journal-title":"Ther Adv Med Oncol"},{"issue":"9944","key":"16412_CR9","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1016\/s0140-6736(14)60845-x","volume":"384","author":"EB Garon","year":"2014","unstructured":"Garon EB, Ciuleanu TE, Arrieta O, et al. Ramucirumab plus docetaxel versus placebo plus docetaxel for second-line treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy (Revel): a multicentre, double-blind, randomised phase 3 trial. Lancet. 2014;384(9944):665\u201373. https:\/\/doi.org\/10.1016\/s0140-6736(14)60845-x.","journal-title":"Lancet"},{"issue":"8","key":"16412_CR10","doi-asserted-by":"publisher","first-page":"752","DOI":"10.1097\/cad.0000000000001330","volume":"33","author":"O Diker","year":"2022","unstructured":"Diker O, Olgun P. Salvage chemotherapy in patients with nonsmall cell lung cancer after prior immunotherapy: a retrospective, real-life experience study. Anticancer Drugs. 2022;33(8):752\u20137. https:\/\/doi.org\/10.1097\/cad.0000000000001330.","journal-title":"Anticancer Drugs"},{"key":"16412_CR11","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1016\/j.lungcan.2020.10.008","volume":"150","author":"M Bersanelli","year":"2020","unstructured":"Bersanelli M, Buti S, Giannarelli D, et al. Chemotherapy in non-small cell lung cancer patients after prior immunotherapy: The multicenter retrospective Clarity study. Lung Cancer. 2020;150:123\u201331. https:\/\/doi.org\/10.1016\/j.lungcan.2020.10.008.","journal-title":"Lung Cancer"},{"issue":"3","key":"16412_CR12","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1200\/jco-24-01544","volume":"43","author":"MJ Ahn","year":"2025","unstructured":"Ahn MJ, Tanaka K, Paz-Ares L, et al. Datopotamab Deruxtecan Versus Docetaxel for Previously Treated Advanced or Metastatic Non-Small Cell Lung Cancer: The Randomized, Open-Label Phase III Tropion-Lung01 Study. J Clin Oncol. 2025;43(3):260\u201372. https:\/\/doi.org\/10.1200\/jco-24-01544.","journal-title":"J Clin Oncol"},{"issue":"20","key":"16412_CR13","doi-asserted-by":"publisher","first-page":"e70324","DOI":"10.1002\/cam4.70324","volume":"13","author":"H Xu","year":"2024","unstructured":"Xu H, Yang Y, Yan Y, et al. Safety and Efficacy of Rechallenge With Immune Checkpoint Inhibitors in Advanced Solid Tumor: A Systematic Review and Meta-Analysis. Cancer Med. 2024;13(20):e70324. https:\/\/doi.org\/10.1002\/cam4.70324.","journal-title":"Cancer Med"},{"issue":"3","key":"16412_CR14","doi-asserted-by":"publisher","first-page":"1787","DOI":"10.21037\/jtd-23-1767","volume":"16","author":"X Yan","year":"2024","unstructured":"Yan X, Zhao L, Wu F, et al. Efficacy and safety analysis of immune checkpoint inhibitor rechallenge therapy in locally advanced and advanced non-small cell lung cancer: a retrospective study. J Thorac Dis. 2024;16(3):1787\u2013803. https:\/\/doi.org\/10.21037\/jtd-23-1767.","journal-title":"J Thorac Dis"},{"issue":"6","key":"16412_CR15","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1038\/s41573-024-00920-9","volume":"23","author":"L Galluzzi","year":"2024","unstructured":"Galluzzi L, Guilbaud E, Schmidt D, et al. Targeting immunogenic cell stress and death for cancer therapy. Nat Rev Drug Discov. 2024;23(6):445\u201360. https:\/\/doi.org\/10.1038\/s41573-024-00920-9.","journal-title":"Nat Rev Drug Discov"},{"key":"16412_CR16","doi-asserted-by":"publisher","unstructured":"Oura K, Morishita A, Tadokoro T, et al. Immune Microenvironment and the Effect of Vascular Endothelial Growth Factor Inhibition in Hepatocellular Carcinoma. Int J Mol Sci. 2024;25(24). https:\/\/doi.org\/10.3390\/ijms252413590.","DOI":"10.3390\/ijms252413590"},{"issue":"20","key":"16412_CR17","doi-asserted-by":"publisher","first-page":"2393","DOI":"10.1200\/jco.23.02166","volume":"42","author":"J Neal","year":"2024","unstructured":"Neal J, Pavlakis N, Kim SW, et al. Contact-01: A Randomized Phase III Trial of Atezolizumab\u2009+\u2009Cabozantinib Versus Docetaxel for Metastatic Non-Small Cell Lung Cancer After a Checkpoint Inhibitor and Chemotherapy. J Clin Oncol. 2024;42(20):2393\u2013403. https:\/\/doi.org\/10.1200\/jco.23.02166.","journal-title":"J Clin Oncol"},{"key":"16412_CR18","doi-asserted-by":"publisher","first-page":"7527","DOI":"10.2147\/dddt.s535615","volume":"19","author":"XS Fang","year":"2025","unstructured":"Fang XS, Zhang TS, Li SJ, et al. Effectiveness and Safety of Anlotinib-Related Therapeutic Regimens in Patients with Previously Immune Checkpoint Inhibitors-Treated Advanced NSCLC: A Real-World Exploratory Study. Drug Des Devel Ther. 2025;19:7527\u201340. https:\/\/doi.org\/10.2147\/dddt.s535615.","journal-title":"Drug Des Devel Ther"},{"issue":"10027","key":"16412_CR19","doi-asserted-by":"publisher","first-page":"1540","DOI":"10.1016\/s0140-6736(15)01281-7","volume":"387","author":"RS Herbst","year":"2016","unstructured":"Herbst RS, Baas P, Kim DW, et al. Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial. Lancet. 2016;387(10027):1540\u201350. https:\/\/doi.org\/10.1016\/s0140-6736(15)01281-7.","journal-title":"Lancet"},{"issue":"3","key":"16412_CR20","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1111\/cas.70242","volume":"117","author":"H Yoshioka","year":"2026","unstructured":"Yoshioka H, Nishio M, Ohashi K, et al. Atezolizumab\u2009+\u2009Chemotherapy for Advanced Non-Small Cell Lung Cancer in Japanese Clinical Practice (J-TAIL-2). Cancer Sci. 2026;117(3):727\u201338. https:\/\/doi.org\/10.1111\/cas.70242.","journal-title":"Cancer Sci"},{"issue":"24","key":"16412_CR21","doi-asserted-by":"publisher","first-page":"e45","DOI":"10.1200\/jco-25-01062","volume":"43","author":"DH Owen","year":"2025","unstructured":"Owen DH, Halmos B, Puri S, et al. Therapy for Stage IV Non-Small Cell Lung Cancer Without Driver Alterations: ASCO Living Guideline, Version 2025.1. J Clin Oncol. 2025;43(24):e45\u201358. https:\/\/doi.org\/10.1200\/jco-25-01062.","journal-title":"J Clin Oncol"},{"key":"16412_CR22","doi-asserted-by":"publisher","unstructured":"Livanou ME, Nikolaidou V, Skouras V, et al. Efficacy of NSCLC Rechallenge with Immune Checkpoint Inhibitors following Disease Progression or Relapse. Cancers (Basel). 2024;16(6). https:\/\/doi.org\/10.3390\/cancers16061196.","DOI":"10.3390\/cancers16061196"},{"key":"16412_CR23","doi-asserted-by":"publisher","first-page":"29","DOI":"10.2147\/lctt.s444884","volume":"15","author":"XJ Dou","year":"2024","unstructured":"Dou XJ, Ma RY, Ren DW, et al. Effectiveness and Safety of Anlotinib Combined with PD-1 Blockades in Patients with Previously Immunotherapy Treated Advanced Non-Small Cell Lung Cancer: A Retrospective Exploratory Study. Lung Cancer (Auckl). 2024;15:29\u201340. https:\/\/doi.org\/10.2147\/lctt.s444884.","journal-title":"Lung Cancer (Auckl)"},{"key":"16412_CR24","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1016\/j.lungcan.2022.09.011","volume":"173","author":"BH Herzog","year":"2022","unstructured":"Herzog BH, Waqar SN, Devarakonda S, et al. Ramucirumab plus atezolizumab in patients with stage IV non-small cell lung cancer previously treated with immune checkpoint inhibitors. Lung Cancer. 2022;173:101\u20136. https:\/\/doi.org\/10.1016\/j.lungcan.2022.09.011.","journal-title":"Lung Cancer"},{"key":"16412_CR25","doi-asserted-by":"publisher","first-page":"101043","DOI":"10.1016\/j.neo.2024.101043","volume":"57","author":"Y Li","year":"2024","unstructured":"Li Y, Zhao J, Li R, et al. Treatment options for tumor progression after initial immunotherapy in advanced non-small cell lung cancer: A real-world study. Neoplasia. 2024;57:101043. https:\/\/doi.org\/10.1016\/j.neo.2024.101043.","journal-title":"Neoplasia"},{"key":"16412_CR26","doi-asserted-by":"publisher","first-page":"517","DOI":"10.18632\/oncotarget.28444","volume":"14","author":"HI Assi","year":"2023","unstructured":"Assi HI, Zerdan MB, Hodroj M, et al. Value of chemotherapy post immunotherapy in stage IV non-small cell lung cancer (NSCLC). Oncotarget. 2023;14:517\u201325. https:\/\/doi.org\/10.18632\/oncotarget.28444.","journal-title":"Oncotarget"},{"issue":"21","key":"16412_CR27","doi-asserted-by":"publisher","first-page":"2295","DOI":"10.1200\/jco.22.00912","volume":"40","author":"KL Reckamp","year":"2022","unstructured":"Reckamp KL, Redman MW, Dragnev KH, et al. Phase II Randomized Study of Ramucirumab and Pembrolizumab Versus Standard of Care in Advanced Non-Small-Cell Lung Cancer Previously Treated With Immunotherapy-Lung-MAP S1800A. J Clin Oncol. 2022;40(21):2295\u2013306. https:\/\/doi.org\/10.1200\/jco.22.00912.","journal-title":"J Clin Oncol"},{"issue":"20","key":"16412_CR28","doi-asserted-by":"publisher","first-page":"17987","DOI":"10.1007\/s00432-023-05490-8","volume":"149","author":"M Xu","year":"2023","unstructured":"Xu M, Hao Y, Shi Z, et al. Efficacy of rechallenge immunotherapy after immune monotherapy resistance in patients with advanced non-small cell lung cancer. J Cancer Res Clin Oncol. 2023;149(20):17987\u201395. https:\/\/doi.org\/10.1007\/s00432-023-05490-8.","journal-title":"J Cancer Res Clin Oncol"},{"issue":"4","key":"16412_CR29","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1007\/s00262-025-03958-9","volume":"74","author":"J Cheng","year":"2025","unstructured":"Cheng J, Kang W, Chen Y, et al. Continuous immunotherapy beyond disease progression in patients with advanced non-small cell and small cell lung cancer. Cancer Immunol Immunother. 2025;74(4):124. https:\/\/doi.org\/10.1007\/s00262-025-03958-9.","journal-title":"Cancer Immunol Immunother"},{"key":"16412_CR30","doi-asserted-by":"publisher","first-page":"1621860","DOI":"10.3389\/fonc.2025.1621860","volume":"15","author":"J Wang","year":"2025","unstructured":"Wang J, Gao Q, Chen J. Efficacy and safety of immune checkpoint inhibitor rechallenge therapy in the treatment of advanced acquired immune-resistant non-small cell lung cancer: a retrospective study. Front Oncol. 2025;15:1621860. https:\/\/doi.org\/10.3389\/fonc.2025.1621860.","journal-title":"Front Oncol"},{"issue":"11","key":"16412_CR31","doi-asserted-by":"publisher","first-page":"105833","DOI":"10.1016\/j.esmoop.2025.105833","volume":"10","author":"IP da Silva","year":"2025","unstructured":"da Silva IP, Zimmer L, Blay JY, et al. Retreatment, rechallenge, and escalation with subsequent immune checkpoint inhibitor therapies across cancers after initial failure. Esmo Open. 2025;10(11):105833. https:\/\/doi.org\/10.1016\/j.esmoop.2025.105833.","journal-title":"ESMO Open"},{"key":"16412_CR32","doi-asserted-by":"publisher","first-page":"217241","DOI":"10.1016\/j.canlet.2024.217241","volume":"604","author":"X Gang","year":"2024","unstructured":"Gang X, Yan J, Li X, et al. Immune checkpoint inhibitors rechallenge in non-small cell lung cancer: Current evidence and future directions. Cancer Lett. 2024;604:217241. https:\/\/doi.org\/10.1016\/j.canlet.2024.217241.","journal-title":"Cancer Lett"},{"issue":"9","key":"16412_CR33","doi-asserted-by":"publisher","first-page":"102315","DOI":"10.1016\/j.xcrm.2025.102315","volume":"6","author":"K Kang","year":"2025","unstructured":"Kang K, Liu S, Yao Z, et al. Addressing clinical needs in NSCLC immunotherapy: Mechanisms of resistance and promising combination strategies. Cell Rep Med. 2025;6(9):102315. https:\/\/doi.org\/10.1016\/j.xcrm.2025.102315.","journal-title":"Cell Rep Med"},{"issue":"1","key":"16412_CR34","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1038\/s41392-022-01270-x","volume":"8","author":"N Xie","year":"2023","unstructured":"Xie N, Shen G, Gao W, et al. Neoantigens: promising targets for cancer therapy. Signal Transduct Target Ther. 2023;8(1):9. https:\/\/doi.org\/10.1038\/s41392-022-01270-x.","journal-title":"Signal Transduct Target Ther"},{"issue":"5","key":"16412_CR35","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1038\/nrclinonc.2018.29","volume":"15","author":"D Fukumura","year":"2018","unstructured":"Fukumura D, Kloepper J, Amoozgar Z, et al. Enhancing cancer immunotherapy using antiangiogenics: opportunities and challenges. Nat Rev Clin Oncol. 2018;15(5):325\u201340. https:\/\/doi.org\/10.1038\/nrclinonc.2018.29.","journal-title":"Nat Rev Clin Oncol"},{"issue":"1","key":"16412_CR36","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1186\/s13046-025-03519-z","volume":"44","author":"H Wang","year":"2025","unstructured":"Wang H, Niu X, Jin Z, et al. Immunotherapy resistance in non-small cell lung cancer: from mechanisms to therapeutic opportunities. J Exp Clin Cancer Res. 2025;44(1):250. https:\/\/doi.org\/10.1186\/s13046-025-03519-z.","journal-title":"J Exp Clin Cancer Res"},{"key":"16412_CR37","doi-asserted-by":"publisher","first-page":"1035323","DOI":"10.3389\/fimmu.2022.1035323","volume":"13","author":"W Zheng","year":"2022","unstructured":"Zheng W, Qian C, Tang Y, et al. Manipulation of the crosstalk between tumor angiogenesis and immunosuppression in the tumor microenvironment: Insight into the combination therapy of anti-angiogenesis and immune checkpoint blockade. Front Immunol. 2022;13:1035323. https:\/\/doi.org\/10.3389\/fimmu.2022.1035323.","journal-title":"Front Immunol"},{"issue":"36","key":"16412_CR38","doi-asserted-by":"publisher","first-page":"4073","DOI":"10.1200\/jco.21.01440","volume":"39","author":"BJ Schneider","year":"2021","unstructured":"Schneider BJ, Naidoo J, Santomasso BD, et al. Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: ASCO Guideline Update. J Clin Oncol. 2021;39(36):4073\u2013126. https:\/\/doi.org\/10.1200\/jco.21.01440.","journal-title":"J Clin Oncol"},{"issue":"1","key":"16412_CR39","doi-asserted-by":"publisher","first-page":"2315","DOI":"10.1038\/s41598-024-52034-2","volume":"14","author":"J Feng","year":"2024","unstructured":"Feng J, Chen X, Wei J, et al. Safety and efficacy of immune checkpoint inhibitor rechallenge in advanced non-small cell lung cancer: a retrospective study. Sci Rep. 2024;14(1):2315. https:\/\/doi.org\/10.1038\/s41598-024-52034-2.","journal-title":"Sci Rep"},{"issue":"9","key":"16412_CR40","doi-asserted-by":"publisher","first-page":"1153","DOI":"10.1007\/s11864-022-00995-9","volume":"23","author":"S Bylsma","year":"2022","unstructured":"Bylsma S, Yun K, Patel S, et al. Immune Checkpoint Inhibitor Rechallenge After Prior Immune Toxicity. Curr Treat Options Oncol. 2022;23(9):1153\u201368. https:\/\/doi.org\/10.1007\/s11864-022-00995-9.","journal-title":"Curr Treat Options Oncol"},{"key":"16412_CR41","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1016\/j.ejca.2021.03.010","volume":"149","author":"E Ghisoni","year":"2021","unstructured":"Ghisoni E, Wicky A, Bouchaab H, et al. Late-onset and long-lasting immune-related adverse events from immune checkpoint-inhibitors: An overlooked aspect in immunotherapy. Eur J Cancer. 2021;149:153\u201364. https:\/\/doi.org\/10.1016\/j.ejca.2021.03.010.","journal-title":"Eur J Cancer"},{"key":"16412_CR42","doi-asserted-by":"publisher","first-page":"671874","DOI":"10.3389\/fonc.2021.671874","volume":"11","author":"H Wang","year":"2021","unstructured":"Wang H, Zhou F, Qiao M, et al. The Role of Circulating Tumor DNA in Advanced Non-Small Cell Lung Cancer Patients Treated With Immune Checkpoint Inhibitors: A Systematic Review and Meta-Analysis. Front Oncol. 2021;11:671874. https:\/\/doi.org\/10.3389\/fonc.2021.671874.","journal-title":"Front Oncol"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12885-026-16412-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-026-16412-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-026-16412-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T23:10:03Z","timestamp":1788909003000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12885-026-16412-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,25]]},"references-count":42,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["16412"],"URL":"https:\/\/doi.org\/10.1186\/s12885-026-16412-5","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,25]]},"assertion":[{"value":"24 March 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This study was performed in line with the principles of the Declaration of Helsinki. Approval was granted by the ethics committee of the First People\u2019s Hospital of Lian Yun Gang (approved number: LW-20260302001-01). The requirement for informed consent was waived because of the retrospective nature of the study. All procedures were performed in accordance with the Declaration of Helsinki.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"1071"}}